CASI Pharmaceuticals Statistics
Share Statistics
CASI Pharmaceuticals has 15.49M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 15.49M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 11.14% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 19.63K, so 0.13% of the outstanding
shares have been sold short.
| Short Interest | 19.63K |
| Short % of Shares Out | 0.13% |
| Short % of Float | 0.17% |
| Short Ratio (days to cover) | 1.28 |
Valuation Ratios
The PE ratio is -1.11 and the forward
PE ratio is -1.14.
CASI Pharmaceuticals's PEG ratio is
-0.04.
| PE Ratio | -1.11 |
| Forward PE | -1.14 |
| PS Ratio | 1.52 |
| Forward PS | 0.3 |
| PB Ratio | 23.45 |
| P/FCF Ratio | -1.47 |
| PEG Ratio | -0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for CASI Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09,
with a Debt / Equity ratio of 11.96.
| Current Ratio | 1.09 |
| Quick Ratio | 0.94 |
| Debt / Equity | 11.96 |
| Debt / EBITDA | -0.64 |
| Debt / FCF | -0.75 |
| Interest Coverage | -45.49 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $122,476.39 |
| Profits Per Employee | $-168,489.27 |
| Employee Count | 233 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 3.31 |
Taxes
| Income Tax | 1.19M |
| Effective Tax Rate | -3.12% |
Stock Price Statistics
The stock price has increased by -25.75% in the
last 52 weeks. The beta is 0.61, so CASI Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.61 |
| 52-Week Price Change | -25.75% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 4.24 |
| Relative Strength Index (RSI) | 45.55 |
| Average Volume (20 Days) | 10,809 |
Income Statement
In the last 12 months, CASI Pharmaceuticals had revenue of 28.54M
and earned -39.26M
in profits. Earnings per share was -2.56.
| Revenue | 28.54M |
| Gross Profit | 11.15M |
| Operating Income | -39.62M |
| Net Income | -39.26M |
| EBITDA | -34.87M |
| EBIT | -37.2M |
| Earnings Per Share (EPS) | -2.56 |
Full Income StatementBalance Sheet
The company has 13.47M in cash and 22.14M in
debt, giving a net cash position of -8.67M.
| Cash & Cash Equivalents | 13.47M |
| Total Debt | 22.14M |
| Net Cash | -8.67M |
| Retained Earnings | -700.08M |
| Total Assets | 53.67M |
| Working Capital | 3.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -29.22M
and capital expenditures -240K, giving a free cash flow of -29.46M.
| Operating Cash Flow | -29.22M |
| Capital Expenditures | -240K |
| Free Cash Flow | -29.46M |
| FCF Per Share | -1.92 |
Full Cash Flow StatementMargins
Gross margin is 39.06%, with operating and profit margins of -138.84% and -137.57%.
| Gross Margin | 39.06% |
| Operating Margin | -138.84% |
| Pretax Margin | -133.4% |
| Profit Margin | -137.57% |
| EBITDA Margin | -122.18% |
| EBIT Margin | -138.84% |
| FCF Margin | -103.25% |
